New guidelines for new treatments in MASLD/MASH: how to diagnose and stage your patient

As metabolic-associated liver disease presents unique challenges in clinical management and is one of the main precursors of liver cancer, Professor Thomas Reiberger reviews updated guidelines on diagnosing and staging MASLD/MASH and explores critical tools and techniques for non-invasive assessments and advanced imaging markers. Viewers learn how to accurately assess disease progression and risk stratification, ensuring that patients receive timely monitoring strategies and treatments.